DRG Market Assessment reports

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

Three anti-VEGF therapies have long been mainstays of treatment in wet age-related macular degeneration (AMD)—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Roche / Genentech’s…

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…